Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Carboplatin 11pembrolizumab 10Paclitaxel 10Fluorouracil 9Oxaliplatin 8Radiotherapy 7Nivolumab 7Leucovorin 6Cisplatin 6Radiotherapy, Intensity-Modulated 5Magnetic Resonance Spectroscopy 5Taxes 4durvalumab 3Trastuzumab 3Surgical Procedures, Operative 3Capecitabine 3relatlimab 2Standard of Care 2Specimen Handling 2Radiation 2Proton Therapy 2Practice Guidelines as Topic 2Irinotecan 2Immune Checkpoint Inhibitors 2Fluorodeoxyglucose F18 2Drug Therapy 2Docetaxel 2Cetuximab 2Blood Specimen Collection 2zimberelimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Esophageal Neoplasms × zanidatamab × Clear all
NCT05152147 2026-05-19

HERIZON-GEA-01

Jazz Pharmaceuticals

Phase 3 Active not recruiting
920 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡